Smith+Nephew Appoints New Non-Executive Director
Ticker: SNNUF · Form: 6-K · Filed: Aug 28, 2025 · CIK: 845982
| Field | Detail |
|---|---|
| Company | Smith & Nephew PLC (SNNUF) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $5.8 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, governance, board-appointment
Related Tickers: SNN
TL;DR
Smith+Nephew adds Dr. Garheng Kong to its board as Non-Executive Director starting Sept 1.
AI Summary
Smith+Nephew announced on August 28, 2025, that Dr. Garheng Kong will join its Board as an independent Non-Executive Director and a member of the Audit Committee, effective September 1, 2025. Dr. Kong brings extensive experience in healthcare and technology to the global medical technology company.
Why It Matters
The addition of a new director with relevant expertise can influence strategic decisions and governance for Smith+Nephew, potentially impacting its future direction in the medical technology sector.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a board appointment and does not contain significant financial or operational news.
Key Players & Entities
- Smith+Nephew (company) — The company making the announcement.
- Dr Garheng Kong (person) — The newly appointed independent Non-Executive Director.
- Audit Committee (company) — The committee Dr. Kong will join.
- August 28, 2025 (date) — Date of the announcement.
- September 1, 2025 (date) — Effective date of the appointment.
FAQ
Who is Dr. Garheng Kong and what is his background?
The filing states Dr. Garheng Kong will join the Board as an independent Non-Executive Director and a member of the Audit Committee, bringing extensive experience in healthcare and technology, though specific details of his background are not provided in this excerpt.
When does Dr. Kong's appointment become effective?
Dr. Garheng Kong's appointment is effective from September 1, 2025.
What committee will Dr. Kong be a part of?
Dr. Garheng Kong will be a member of the Audit Committee.
What is the filing type and date?
This is a Form 6-K filed on August 28, 2025.
What is Smith+Nephew's primary business?
Smith+Nephew is described as a global medical technology company.
Filing Stats: 989 words · 4 min read · ~3 pages · Grade level 15.4 · Accepted 2025-08-28 06:35:28
Key Financial Figures
- $5.8 billion — countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent
Filing Documents
- a9485w.htm (6-K) — 28KB
- 0001654954-25-010114.txt ( ) — 29KB
Forward-looking Statements
Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at ww
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.             Smith & Nephew plc     (Registrant)             Date: August 28, 2025 By: /s/ Helen Barraclough     Helen Barraclough     Company Secretary